[HTML][HTML] Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review
CAC Jessurun, JAM Vos, J Limpens… - Frontiers in oncology, 2017 - frontiersin.org
Background Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …
[PDF][PDF] Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
CAC Jessurun, JAM Vos, J Limpens… - Frontiers in …, 2017 - academia.edu
Background: Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …
[HTML][HTML] Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
CAC Jessurun, JAM Vos, J Limpens… - Frontiers in …, 2017 - ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
CAC Jessurun, JAM Vos, J Limpens… - Frontiers in …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have
shown impressive therapeutic results. However, only 20-40% of advanced melanoma …
shown impressive therapeutic results. However, only 20-40% of advanced melanoma …
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
CAC Jessurun, JAM Vos… - Frontiers in …, 2017 - researchinformation.amsterdamumc …
Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have shown
impressive therapeutic results. However, only 20-40% of advanced melanoma patients have …
impressive therapeutic results. However, only 20-40% of advanced melanoma patients have …
[PDF][PDF] Biomarkers for Response of melanoma Patients to immune checkpoint inhibitors: a Systematic Review
CAC Jessurun, JAM Vos, J Limpens… - Frontiers in …, 2017 - scienceopen.com
Background: Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
CAC Jessurun, JAM Vos, J Limpens… - Frontiers in …, 2017 - europepmc.org
BACKGROUND: Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules,
have shown impressive therapeutic results. However, only 20-40% of advanced melanoma …
have shown impressive therapeutic results. However, only 20-40% of advanced melanoma …
[引用][C] Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
CAC Jessurun, JAM Vos, J Limpens, RM Luiten - Frontiers in Oncology, 2017 - cir.nii.ac.jp
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A
Systematic Review | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
Systematic Review | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …